Rufus Pichler is a partner in the San Francisco office of Morrison & Foerster LLP and has been a member of the firm's Technology Transactions Group for over fifteen years. His practice focuses primarily on commercial transactions involving technology and intellectual property. Among other things, Mr. Pichler advises companies in the wireless, computer and IT, semiconductor, biotechnology and pharmaceutical industries with respect to in- and out-licenses, cross-licensing arrangements, development, joint venture and collaboration, manufacturing, supply and distribution agreements and other transactions. In particular, Mr. Pichler has advised clients extensively in connection with complex patent licensing transactions, including patent exhaustion issues, patent sales and acquisitions, patent strategy, and intellectual property aspects of M&A transactions, both in the U.S. and other jurisdictions.
Mr. Pichler has specific expertise in international intellectual property and commercial law including European Union and German law, and has advised clients from the United States and abroad in a variety of international transactions. He is admitted to practice in New York, California, and Germany and has advised clients from the United States and abroad in a variety of international transactions and with respect to global intellectual property protection strategies. Mr. Pichler holds advanced degrees in law in the U.S. and Germany.
Mr. Pichler served as adjunct professor at the University of San Francisco School of Law, where he taught International Intellectual Property Law, and has published several books and articles in the field of intellectual property and technology law. In 2005/2006, Mr. Pichler served as the Global Engelberg Fellow from Practice at the Engelberg Center for Innovation Law and Policy at New York University's School of Law where he conducted research on issues surrounding the patent exhaustion and implied license doctrines.
Mr. Pichler is listed in Chambers USA 2014 as an “Up & Coming” attorney in New York Technology & Outsourcing. Chambers states that Mr. Pichler is “hands down a go-to attorney for his diligence and creativity’.” He is also recommended by Legal 500 US as "a uniquely technically sound and diligent lawyer" for his patent licensing and transactional work. Mr.Pichler is recommended by IAM Patent 1000 and described as “an excellent scholar and technician” with “a great sense in terms of balancing what is and what is not important [and] the potential to get to the top level of the market.”
Mr. Pichler received his law degree (J.D.) from the University of Freiburg, Germany, in 1995. He also holds a J.S.M. (Master of the Science of Law) degree from Stanford Law School and a Ph.D. (Dr. iur.) from the University of Münster, Germany.
Mr. Pichler's clients include, among others, Altera, Astellas, Atmel, Autodesk, Dow Jones & Company, DSP Group, Elpida, Fujitsu, Hitachi, Intel, Mediatek, Mitsubishi Electric, Moody’s, Murex, Otto Group, Panasonic, and Toshiba.
Intel Corporation on IP issues in connection with its $650 million acquisition of LSI’s Axxia Networking Business from Avago Technologies Limited.
Intel Corporation in its strategic alliance with China-based Tsinghua Unigroup and Spreadtrum Communications for the design and marketing of Intel architecture-based mobile SoC platforms for smartphones.
Intel Corporation in its strategic alliance with China-based Rockchip for the design and marketing of Intel architecture-based mobile SoC platforms for tablets.
Netlist, Inc. on a loan and patent monetization transaction with Fortress Investment Group LLC.
Intel Corporation on IP issues in connection with its acquisition of Intelligent Dialogue Systems, S.L. (Indisys), a Spanish company that provides businesses with natural language and dialogue management solutions.
Intel Corporation on IP issues in connection with its acquisition of Mashery.
NCR Corporation on IP issues in connection with its acquisition of Israel-based retail software and services company Retalix Ltd., a stock purchase transaction valued at approximately $650 million and the largest public acquisition of an Israeli company announced in 2012.
Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. in a transaction with Bayer for the marketing and co-promotion of VEGF Trap-Eye (for treatment of age-related macular degeneration) in Japan.
Gree Inc. on IP issues in connection with its acquisition of mobile social games developer Funzio, Inc.
Intel Corporation on its $375 million acquisition from InterDigital of roughly 1,700 patents and patent applications primarily related to wireless communication technologies.
Threshold Pharmaceuticals in its agreement with Merck KGaA for the development and commercialization of Threshold’s cancer candidate, TH-302, with Threshold receiving up to $550 million in upfront fees and potential development and commercialization milestone payments as well as royalties.
Intel Corporation on IP issues in connection with its $1.4 billion purchase of Infineon Technologies AG’s Wireless Solutions business.
On Semiconductor Corporation
On Semiconductor Corporation on IP issues in connection with its $31 million acquisition of Cypress Semiconductor Corporation’s image sensor business unit.
Advanced Micro Fabrication Equipment, Inc.
Advanced Micro Fabrication Equipment, Inc. (AMEC), on IP issues in connection with settlement of certain disputes with Applied Materials, Inc.
EW Scripps and United Media
EW Scripps and United Media on IP issues in connection with their sale of rights in Charles Schulz’s “Peanuts” comic strips and characters to Iconix Brand Group and Schulz’s heirs.
Major consumer products company
A major consumer products company on copyright and other IP issues in connection with an online music talent competition.
Otto Group in its acquisition of the “Bombay” trademarks and related assets from Hilco Consumer Capital and Gordon Brothers Group.
Nikon Metrology on settlement and commercial agreements with Hexagon Metrology related to coordinate measuring arms.
Astellas Pharmaceuticals, Inc.
Astellas Pharmaceuticals, Inc., on license agreement with Ironwood Pharmaceuticals regarding the exclusive development and commercialization by Astellas of Ironwood’s linaclotide compound in Asia.
Gruppo Campari on IP issues in connection with its $575M purchase of the Wild Turkey brand and related assets from Pernod Ricard.
Freescale Semiconductor, Inc.
Freescale Semiconductor, Inc., on IP issues in connection with the sale of its Imaging Systems Group to Conexant Systems, Inc.
Leading supplier of mobile handsets
A leading supplier of mobile handsets on license and collaboration agreements with major semiconductor companies regarding the design and supply of 3G chipsets.
Freescale Semiconductor, Inc.
Freescale Semiconductor, Inc., on IP issues in connection with the sale of its Gallium Arsenide (GaAs) power amplifier business to Skyworks Solutions, Inc.
Intercell AG on marketing and distribution agreement with Novartis for Intercell’s Japanese Encephalitis vaccine in Europe, the U.S., and certain other markets.
Nikon Corporation on license agreement with KLA Tencor, Inc. related to overlay measuring equipment.
Intercell AG in its strategic alliance with Biological E Ltd. for development, manufacture, and commercialization of Japanese Encephalitis vaccine in Asia.
Intercell AG on several agreements with Merck & Co., Inc., regarding the development and commercialization of a vaccine against Group A Streptococcus and Staphylococcus aureus infections.
Nikon Corporation on complex settlement and cross-license agreements with ASML Holding N.V. and Carl Zeiss SMT AG related to lithography equipment.
Fujitsu Limited on IP and commercial law issues in its collaboration with Sun Microsystems, Inc. (now Oracle), regarding the development and commercialization of server products.